P.O. Box 30449
Salt Lake City, UT 84130-0449

Clozapine Risk Evaluation and Mitigation Strategies Program Update (Effective February 24, 2025)

The U.S. Food & Drug Administration (FDA) announced that prescribing clinicians and pharmacies are no longer required to upload patient data, including registration details and absolute neutrophil count (ANC) lab results, to the Clozapine Risk Evaluation and Mitigation Strategies (REMS) program. However, the FDA continues to recommend that prescribers monitor patients' ANC as outlined in the prescribing information. The FDA will collaborate with clozapine manufacturers in the coming months to update the prescribing information and work toward eliminating the clozapine REMS program entirely.

Read more from the FDA...